Deciphera Pharmaceuticals Llc Stock Today
| DCPH Stock | USD 25.36 0.09 0.36% |
Performance9 of 100
| Odds Of DistressLess than 9
|
Deciphera Pharmaceuticals is trading at 25.36 as of the 2nd of May 2024. This is a 0.36 percent increase since the beginning of the trading day. The stock's open price was 25.27. Deciphera Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. Equity ratings for Deciphera Pharmaceuticals LLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of April 2024 and ending today, the 2nd of May 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of September 2017 | Category Healthcare | Classification Health Care |
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. The company has 82.23 M outstanding shares of which 5.75 M shares are currently shorted by private and institutional investors with about 10.9 trading days to cover. More on Deciphera Pharmaceuticals LLC
Deciphera Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Deciphera Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Deciphera Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Michael Taylor | ||||
| Thematic Idea | Cancer Fighters (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Cancer Fighters, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering Deciphera Pharmaceuticals report their recommendations after researching Deciphera Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Deciphera Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Deciphera Pharmaceuticals. The Deciphera consensus assessment is calculated by taking the average forecast from all of the analysts covering Deciphera Pharmaceuticals. | |||||
Deciphera Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Deciphera Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Deciphera Pharmaceuticals' financial leverage. It provides some insight into what part of Deciphera Pharmaceuticals' total assets is financed by creditors.
| |||||
Deciphera Pharmaceuticals LLC (DCPH) is traded on NASDAQ Exchange in USA. It is located in 200 Smith Street, Waltham, MA, United States, 02451 and employs 355 people. Deciphera Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.09 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Deciphera Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Deciphera Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Deciphera Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 82.23 M outstanding shares of which 5.75 M shares are currently shorted by private and institutional investors with about 10.9 trading days to cover.
Deciphera Pharmaceuticals LLC currently holds about 383.85 M in cash with (146.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74.
Check Deciphera Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationDeciphera Pharmaceuticals retains a total of 82.23 Million outstanding shares. The majority of Deciphera Pharmaceuticals LLC outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Deciphera Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Deciphera Pharmaceuticals. Please pay attention to any change in the institutional holdings of Deciphera Pharmaceuticals LLC as this could imply that something significant has changed or is about to change at the company. Also note that almost one million six hundred fourty-four thousand five hundred twenty invesors are currently shorting Deciphera Pharmaceuticals expressing very little confidence in its future performance.
Check Deciphera Ownership Details
Deciphera Stock Price Odds Analysis
Coming from a normal probability distribution, the odds of Deciphera Pharmaceuticals jumping above the current price in 90 days from now is near 1%. The Deciphera Pharmaceuticals LLC probability density function shows the probability of Deciphera Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.7388 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Deciphera Pharmaceuticals will likely underperform. Moreover, deciphera Pharmaceuticals LLC has an alpha of 1.0365, implying that it can generate a 1.04 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Deciphera Pharmaceuticals to move above the current price in 90 days from now is near 1 (This Deciphera Pharmaceuticals LLC probability density function shows the probability of Deciphera Stock to fall within a particular range of prices over 90 days) .
Deciphera Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Deciphera Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Deciphera Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Deciphera Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Nuveen Asset Management, Llc | 2023-12-31 | 1.4 M | |
| Geode Capital Management, Llc | 2023-12-31 | 1.2 M | |
| Jefferies Financial Group Inc | 2023-12-31 | 917.5 K | |
| Assenagon Asset Management Sa | 2024-03-31 | 809.9 K | |
| Jacobs Levy Equity Management, Inc. | 2023-09-30 | 707.1 K | |
| Emerald Advisers, Llc | 2023-12-31 | 671.3 K | |
| Millennium Management Llc | 2023-12-31 | 652.3 K | |
| Point72 Asset Management, L.p. | 2023-09-30 | 598.1 K | |
| New Leaf Venture Partners, L.l.c. | 2023-12-31 | 577 K | |
| Deerfield Management Co | 2023-09-30 | 6.9 M | |
| Blackrock Inc | 2023-12-31 | 6 M |
Deciphera Pharmaceuticals Historical Income Statement
Deciphera Pharmaceuticals LLC Income Statement is one of the three primary financial statements used for reporting Deciphera's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Deciphera Pharmaceuticals revenue and expense. Deciphera Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Deciphera Pharmaceuticals' Total Revenue is increasing as compared to previous years. The Deciphera Pharmaceuticals' current Gross Profit is estimated to increase to about 167.6 M, while Selling General Administrative is projected to decrease to under 74.7 M. View More FundamentalsDeciphera Stock Against Markets
Picking the right benchmark for Deciphera Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Deciphera Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Deciphera Pharmaceuticals is critical whether you are bullish or bearish towards Deciphera Pharmaceuticals LLC at a given time. Please also check how Deciphera Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Deciphera Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
Deciphera Pharmaceuticals Corporate Directors
Deciphera Pharmaceuticals corporate directors refer to members of a Deciphera Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Deciphera Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Deciphera Pharmaceuticals' board members must vote for the resolution. The Deciphera Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| John Martin | Independent Director | Profile | |
| Patricia Allen | Independent Director | Profile | |
| Susan Kelley | Director | Profile | |
| Liam Ratcliffe | Independent Director | Profile |
How to buy Deciphera Stock?
Before investing in Deciphera Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Deciphera Pharmaceuticals. To buy Deciphera Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Deciphera Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Deciphera Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Deciphera Pharmaceuticals LLC stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Deciphera Pharmaceuticals LLC stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Deciphera Pharmaceuticals LLC, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Deciphera Stock please use our How to Invest in Deciphera Pharmaceuticals guide.
Already Invested in Deciphera Pharmaceuticals LLC?
The danger of trading Deciphera Pharmaceuticals LLC is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Deciphera Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Deciphera Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Deciphera Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Deciphera Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Deciphera Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Deciphera Pharmaceuticals Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Deciphera Pharmaceuticals Llc Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Deciphera Pharmaceuticals LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Deciphera Stock analysis
When running Deciphera Pharmaceuticals' price analysis, check to measure Deciphera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Deciphera Pharmaceuticals is operating at the current time. Most of Deciphera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Deciphera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Deciphera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Deciphera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Deciphera Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Deciphera Pharmaceuticals. If investors know Deciphera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Deciphera Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.29) | Revenue Per Share 1.92 | Quarterly Revenue Growth 0.329 | Return On Assets (0.28) | Return On Equity (0.56) |
The market value of Deciphera Pharmaceuticals is measured differently than its book value, which is the value of Deciphera that is recorded on the company's balance sheet. Investors also form their own opinion of Deciphera Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Deciphera Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Deciphera Pharmaceuticals' market value can be influenced by many factors that don't directly affect Deciphera Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Deciphera Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Deciphera Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Deciphera Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.